Use of immunomodulating agents

Details Use of immunomodulating agents Use of immunomodulating agents

2007-03-20

2007-03-20

Schultz, James (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S047000, C514S261100, C536S027130, C536S027140, C536S027200, C544S264000

Reexamination Certificate

active

09428458

ABSTRACT:
Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.

REFERENCES:
patent: 4568676 (1986-02-01), Smith
patent: 5276017 (1994-01-01), Feinberg
patent: 5843916 (1998-12-01), Cho-Chung et al.
patent: WO 9319766 (1993-10-01), None
patent: WO 93/21929 (1993-11-01), None
patent: WO 9321929 (1993-11-01), None
patent: WO 9416736 (1994-08-01), None
patent: WO 9704096 (1997-02-01), None
patent: WO 9711171 (1997-03-01), None
Bjorn T. Gjertsen et al., Novel (Rp)-cAMPS Analogs as Tools for Inhibition of cAMP-kinase in Cell Culture. The Journal of Biological Chemistry, vol. 270, No. 35, pp. 20599-20607, Sep. 1, 1995.
C.C. Chinery et al., Department of General Surgery.
Punch et al. Opposite Modulation of Opiate Withdrawal Behaviors on Microinfusion of a Protein Kinase A Inhibitor Versus Activator into the Locus Coeruleus or Periaqueductal Gray. The Journal of Neuroscience. Nov. 1, 1997, vol. 17, No. 21, pp. 8520-8527.
Jackson, William Pharmacology 1996, 52:226-234.
Ogreid et al., (Rp)- and (Sp)-8-piperidino-adenosine 3′,5′-(cyclic)thiophosphates discriminate completely between site A and B of the regulatory subunits of cAMP-dependent protein kinase type I and II, 1994, Eur J Biochem., 221(3), pp. 1089-1094.
Gjertsen et al., Novel (Rp)-cAMPs Analogs as Tools for Inhibition of cAMP-kinase in Cell Culture, 1995, The Journal of Biological Chemistry, vol. 270, No. 35, pp. 20599-20607.
Hofmann et al., Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues, 1993, AIDS, vol. 7, No. 5, pp. 659-664.
Mochly-Rosen,Science, 268:247-251 (1995).
Skålhegg et al,Science, 263:84-87 (1994).
Levy et al,Eur. J. Immunol, 26:1290-1296. (1996).
Torgersen et al,J. Biol. Chem., 272(9):5495-5500 (1997).
Skalhegg et al,Frontiers in Bioscience 2, pp. d331-342 (1997).
Hofmann et al,AIDS, 7:659-664 (1993), pp. 659 and 663 Only.
Øgreid et al,European J. of Biochem., 227:1089-1094 (1994).
Dostmann et al,J. of Biological Chemistry, 265(18)10484-10491 (1990).
Cho-Chung,Antisense Nucleic Acid Drug Dev., 6(3)234-244 (1996 Fall), Abstract Only.
Hoffman et al,AIDS, 7:659-664 (1993).
Skålhegg et al,J. of Biological Chemistry, 267(22):15717-15714 (1992).

Affiliated with

Also associated with

Rating

Use of immunomodulating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of immunomodulating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of immunomodulating agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3750948